LFA-1 as a Key Regulator of Immune Function: Approaches toward the Development of LFA-1-Based Therapeutics

E-ISSN： 1873-4286|12|22|2771-2795

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.12, Iss.22, 2006-08, pp. : 2771-2795

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel hydantoin derivatives useful as LFA-1 antagonists

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 1, 1999-01 ,pp. : 97-99

Informa Healthcare

Access to resources Recommend Favorite

Alefacept: Amevive, BG 9273, Human LFA-3/Igg Fusion Protein, LFA 3, LFA 3 TIP, LFA 3/CD2, LFA-3/Igg Fusion Protein, LFA3TIP, Recombinant LFA-3/Igg1 Human Fusion Protein, Recombinantly Engineered LFA-1/Igg1 Human Fusion Protein

Drugs in R&D, Vol. 3, Iss. 1, 2002-01 ,pp. : 21-24

Adis International

Access to resources Recommend Favorite

LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery

Current Pharmaceutical Design, Vol. 16, Iss. 21, 2010-07 ,pp. : 2321-2330

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents

By Liu Gang

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 9, 2001-09 ,pp. : 1383-1393

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors Targeting the LFA-1/ICAM-1 Cell-Adhesion Interaction: Design and Mechanism of Action

Current Pharmaceutical Design, Vol. 14, Iss. 22, 2008-08 ,pp. : 2128-2139

Bentham Science Publishers

Access to resources Recommend Favorite